Why the study?
Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex clinical decision.
What are the preferences of cardiologists in Türkiye regarding antiplatelet treatment and DAPT duration in coronary artery disease?
What are the preferences of cardiologists in Türkiye regarding antiplatelet treatment and DAPT duration in coronary artery disease?
A survey of Turkish cardiologists reveals that their preferences for DAPT duration and P2Y12 inhibitor selection in coronary artery disease show both adherence to and deviations from current guidelines.
Answers are grounded in this paper and cite their sources.
Survey preferences show partial guideline alignment in Türkiye; leaves open whether targeted education can close deviations in CCS.
OBJECTIVE: Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex decision. This survey aims to explore the preferences for antiplatelet therapy and the daily routine regarding DAPT duration in coronary artery disease among a group of cardiologists in Türkiye. METHOD: Using an online questionnaire with 38 questions, the preferences of 314 cardiologists were collected. Qualitative descriptive characteristics of the answers received from the participants were examined. RESULTS: Participating cardiologists mostly worked in training and research hospitals (51.59%) and university hospitals (21.66%). Participants primarily favored ticagrelor in patients undergoing PCI with a diagnosis of STEMI and NSTE-ACS (69.75% and 55.73% respectively). Clopidogrel was the most preferred P2Y12 treatment in patients with chronic coronary syndrome (CCS) after PCI (94.90%). Pre-treatment with a loading dose of a P2Y12 receptor inhibitor was administered to 57.01% of patients with NSTE-ACS, irrespective of the planned treatment strategy. In NSTE-ACS patients with low bleeding risk treated with PCI, 83.12% of participants recommended DAPT for 12 months and 14.65% for >12 months. In high-bleeding-risk NSTE-ACS patients treated with PCI, DAPT durations of six months (74.52%), three months (19.75%), and one month (5.73%) were chosen. Among CCS patients treated with PCI without an increased risk of bleeding, 12 months of DAPT was preferred by 68.15% of participants. Most participants (70.70%) were switching to a more potent P2Y12 receptor inhibitor therapy in emergency department clopidogrel-loaded patients with ACS. CONCLUSION: The aim of this survey to capture a snapshot of the preferences of a group of cardiologists in Türkiye regarding DAPT treatment and duration. The responses were both in accordance and in conflict with the current guidelines.
No takes yet. Share an insight, caveat, or question.
Özge Çetinarslan (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: